口服格列本脲治疗早发性高血糖 (GALOP) (GALOP)
The purpose of this study is to confirm hypothesis that Glibenclamide can be administered orally and is an alternative to insulin therapy in treating transient hyperglycemia of premature newborns.
研究概览
地位
详细说明
Transient hyperglycemia of premature newborns results from an overall decrease in insulin sensitivity, which is responsible at the beta cell level for abnormalities of intragranular cleavage of proinsulin into insulin, leading to reduced active insulin secretion. Intravenous administration of exogenous insulin can be used to combat insulin resistance and lower blood glucose, but it is difficult to manage in premature newborns and is associated with a substantial risk of hypoglycemia. Glibenclamide, which stimulates endogenous insulin secretion and can be administered orally, might be an alternative to insulin therapy in treating transient hyperglycemia of premature newborns.
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
-
Paris、法国、75015
- Hopital Necker - Enfants malades
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Newborn less than 34 week of amenorrhea corrected age
- Birth weight < 1500 g
- Birth term < 32 week of amenorrhea
- Hyperglycemia ≥ 10 mmol/l in 2 measurements, 3 hours apart after potential reduction of glucose intakes following each department's protocol
- Secure venous access point (umbilical venous catheter or epicutaneo-cava catheter)
- Enteral feeding considered before inclusion or already established
- Consent obtained from persons holding parental authority
- Beneficiary of social security
Exclusion Criteria
- Contraindication to enteral feeding (at the discretion of the clinician responsible for the child)
- Contraindication to glibenclamide according to current SPC
- Foetal growth restriction (FGR) birth weight < 3rd percentile (AUDIPOG definition)
- Severe birth defect, including cardiac malformation associated with a risk of myocardial ischemia
- Severe sepsis requiring mechanical ventilation or haemodynamic support
- Severe renal dysfunction (serum creatinine > 120 µmol/l)
- Severe hepatocellular failure (V factor less than the standard laboratory range for the age) and/or severe cholestasis (> 50 µmol/L)
- Hyperglycemia associated with an error in administering glucose infusion
- Profound hypophosphoremia (< 1 mmol/l)
- Hypersensitivity to glibenclamide or other sulphonylureas or sulphonamides, or one of the excipients
- Patient with continuous insulin IV administration
- Patient treated with miconazole
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Glibenclamide oral
Amglidia®: glibenclamide oral suspension 6 mg/ml administered by gastric tube after dilution to 1/6th in human milk |
Amglidia®: glibenclamide oral suspension 6 mg/ml administered by gastric tube after dilution to 1/6th in human milk
PK parameters of glibenclamide will be determined using nonlinear analysis: area under the plasma concentration time curve (AUC), absorption constant, apparent clearance and volume of distribution. blood sampling at before first administration and after 24 hours for measurement of C-peptide proinsulin ratio if it is impossible to collect both volumes, the C-peptide collection will be prioritized If there are not performed as part of standard care, biological monitoring of ALT, AST, complete blood count, hemostasis, urea, creatinine, blood ionogram, total bilirubin and conjugated bilirubin will be done before first administration at the following time frame : 48 hours after the first administration than each days during treatment period, and 48 hours after the end of treatment. Transaminases and hemostasis will be done only in case of clinical indication before the first administration. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Blood glucose control
大体时间:At 72 hours after the first administration
|
The primary evaluation criteria is 72 hours blood glucose control on glibenclamide treatment (success of the treatment). This is defined as the non-use of insulin and absence of severe hypoglycemia (< 1.5 mmol/l) or persistent moderate hypoglycemia (< 2.6 mmol/l in 2 successive measurements (dextro) at an interval of more than 3 hours) |
At 72 hours after the first administration
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Overall success of the treatment
大体时间:At 36 week of amenorrhea corrected age
|
Overall success of the treatment defined by continuation to the end of treatment without recourse to insulin. |
At 36 week of amenorrhea corrected age
|
|
Blood glucose profile on glibenclamide
大体时间:At the end of treatment assessed up to 15 days
|
Time between the start of glibenclamide treatment and the 1st blood glucose < 10 mmol/l |
At the end of treatment assessed up to 15 days
|
|
Blood glucose profile on glibenclamide
大体时间:At the end of treatment assessed up to 15 days
|
Time between the start of glibenclamide treatment and the 1st blood glucose < 8 mmol/l |
At the end of treatment assessed up to 15 days
|
|
Blood glucose profile on glibenclamide
大体时间:At the end of treatment assessed up to 15 days
|
Proportion of time spent within the target blood glucose range (≥ 4 and < 10 mmol/l) during the period of glibenclamide treatment |
At the end of treatment assessed up to 15 days
|
|
Blood glucose profile on glibenclamide
大体时间:At the end of treatment assessed up to 15 days
|
Proportion of time spent above the target level (≥ 10 mmol/l) during the period of glibenclamide treatment |
At the end of treatment assessed up to 15 days
|
|
Blood glucose profile on glibenclamide
大体时间:At the end of treatment assessed up to 15 days
|
Proportion of time spent in hypoglycemia (< 2.6 mmol/l) during the period of glibenclamide treatment |
At the end of treatment assessed up to 15 days
|
|
Duration of glibenclamide treatment
大体时间:At the end of treatment assessed up to 15 days
|
Duration of glibenclamide treatment. |
At the end of treatment assessed up to 15 days
|
|
Nutritional intakes and growth
大体时间:At the end of treatment assessed up to 15 days
|
Carbohydrate |
At the end of treatment assessed up to 15 days
|
|
Nutritional intakes and growth:
大体时间:At the end of treatment assessed up to 15 days
|
lipid |
At the end of treatment assessed up to 15 days
|
|
Nutritional intakes and growth:
大体时间:At the end of treatment assessed up to 15 days
|
protein |
At the end of treatment assessed up to 15 days
|
|
Nutritional intakes and growth:
大体时间:At the end of treatment assessed up to 15 days
|
mean caloric intake (kcal/kg/day) during treatment |
At the end of treatment assessed up to 15 days
|
|
Nutritional intakes and growth:
大体时间:At the end of treatment assessed up to 15 days
|
mean weight gain (g/kg/day) |
At the end of treatment assessed up to 15 days
|
|
Nutritional intakes and growth
大体时间:At 36 week of amenorrhea corrected age
|
Carbohydrate |
At 36 week of amenorrhea corrected age
|
|
Nutritional intakes and growth:
大体时间:At 36 week of amenorrhea corrected age
|
lipid |
At 36 week of amenorrhea corrected age
|
|
Nutritional intakes and growth:
大体时间:At 36 week of amenorrhea corrected age
|
protein |
At 36 week of amenorrhea corrected age
|
|
Nutritional intakes and growth:
大体时间:At 36 week of amenorrhea corrected age
|
mean caloric intake (kcal/kg/day) during treatment |
At 36 week of amenorrhea corrected age
|
|
Nutritional intakes and growth:
大体时间:At 36 week of amenorrhea corrected age
|
mean weight gain ((g/kg/day) |
At 36 week of amenorrhea corrected age
|
|
Number of children with episode of hypoglycemia
大体时间:At 72 hours after first administration
|
Number of children with at least one episode of moderate (blood glucose < 2.6 mmol/l) or severe (< 1.5 mmol/l) hypoglycemia |
At 72 hours after first administration
|
|
Number of children with episode of hypoglycemia
大体时间:At the end of treatment assessed up to 15 days
|
Number of children with at least one episode of moderate (blood glucose < 2.6 mmol/l) or severe (< 1.5 mmol/l) hypoglycemia |
At the end of treatment assessed up to 15 days
|
|
Type of adverse reactions on glibenclamide
大体时间:At 36 week of amenorrhea corrected age
|
evaluation of the type of adverse reactions identified during the study |
At 36 week of amenorrhea corrected age
|
|
Number of adverse reactions on glibenclamide
大体时间:At 36 week of amenorrhea corrected age
|
evaluation of number of adverse reactions identified during the study |
At 36 week of amenorrhea corrected age
|
|
Number of participants with co-morbidity
大体时间:At 36 week of amenorrhea corrected age
|
Neonatal morbidity assessed at 36 WA corrected age: intraventricular haemorrhage, periventricular leukomalacia, retinopathy of premature newborns, haemodynamic disorders, ulcerative necrotising enterocolitis |
At 36 week of amenorrhea corrected age
|
|
Mortality
大体时间:At 36 week of amenorrhea corrected age
|
Mortality will be assessed |
At 36 week of amenorrhea corrected age
|
|
Dose adjustment
大体时间:At the end of treatment assessed up to 15 days
|
Number of dose adjustments, to evaluate the easy of use |
At the end of treatment assessed up to 15 days
|
|
ease of use by caregivers
大体时间:At day one of treatment
|
Assessment scores by visual-analogue scale for ease of use by caregivers; 0 as the lowest score, 10 as the highest score |
At day one of treatment
|
|
ease of use by caregivers
大体时间:At day two of treatment
|
Assessment scores by visual-analogue scale for ease of use by caregivers; 0 as the lowest score, 10 as the highest score |
At day two of treatment
|
|
ease of use by caregivers
大体时间:At day three of treatment
|
Assessment scores by visual-analogue scale for ease of use by caregivers; 0 as the lowest score, 10 as the highest score |
At day three of treatment
|
|
Plasma concentrations of glibenclamide
大体时间:At 3 hours after the first administration
|
Evaluated by the pharmacokinetics study |
At 3 hours after the first administration
|
|
Plasma concentrations of glibenclamide
大体时间:At 6 hours after the first administration
|
Evaluated by the pharmacokinetics study |
At 6 hours after the first administration
|
|
Plasma concentrations of glibenclamide
大体时间:At 10 hours after the first administration
|
Evaluated by the pharmacokinetics study |
At 10 hours after the first administration
|
|
Plasma concentrations of glibenclamide
大体时间:At 24 hours after the first administration
|
Evaluated by the pharmacokinetics study |
At 24 hours after the first administration
|
|
Plasma concentrations of glibenclamide
大体时间:At 24 hours of blood glucose stabilization
|
Evaluated by the pharmacokinetics study |
At 24 hours of blood glucose stabilization
|
合作者和调查者
调查人员
- 研究主任:Jacques BELTRAND, Pr、Assistance Publique - Hôpitaux de Paris
- 研究主任:Michel POLAK、Assistance Publique - Hôpitaux de Paris
- 研究主任:Delphine MITANCHEZ、CHRU de Tours
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.